Latest news with #clinicalResearch
The Independent
3 days ago
- Health
- The Independent
Eating this kind of bread can raise colon cancer patients' risk of death
Eating white bread and other foods considered to be proinflammatory can raise colon cancer patients' risk of death from the disease, researchers said this week. Of a study of more than 1,600 patients with stage III colon cancer, people who consumed the most of those foods — also including french fries, hot dogs, and soda — during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet. The patients who ate a proinflammatory diet had an 87 percent higher risk of death than those who consumed the least proinflammatory food. Inflammation is the body's immune response to stimulus, such as falling down or burning your finger. Both too little and too much inflammation can cause problems, and most chronic diseases are believed to be rooted in inflammation that lasts over time. Some of the foods that can contribute to inflammation have been linked to cancer risk. 'One of the most common questions that patients ask is what they should do after treatment to maximally reduce their risk of cancer recurrence and improve survival,' Dr. Sara Char, a clinical fellow in hematology and oncology at Boston's Dana-Farber Cancer Institute, said in a statement. 'These findings add to the published literature about the importance of dietary patterns and physical activity in outcomes of patients with colorectal cancer.' Char was the first author of the research which was presented on Sunday at this year's American Society of Clinical Oncology Annual Meeting. 'This study provides additional evidence that diet may be important for improving outcomes and survival in patients with stage III colon cancer,' co-author Dr. Kimmie Ng, also of Dana-Farber, said. 'Further studies are needed to tailor specific dietary recommendations for patients with colon cancer, and to understand the biological mechanisms underlying the relationship between proinflammatory diets and survival.' The use of the anti-inflammatory drug in the participants' trial, which is known as celecoxib, did not have a significant influence on the relationship between diet and survival, but the authors also noted that those who engaged in higher levels of physical activity had the best overall survival outcomes. Their findings come following previous research that showed systemic inflammation can increase the risk of colon cancer development and progression. Using anti-inflammatory drugs can reduce the risk of recurrence in selected patients with stage III colon cancer, the Dana-Farber researchers said. It remains unclear how much diet could affect cancer outcomes after treatment, but these findings add to a growing body of knowledge that could affect tens of thousands of Americans with colorectal cancer. Some 150,000 people are diagnosed with colorectal cancer each year in the U.S. It is the second-most common cause of cancer deaths for men and women in the U.S., and is expected to cause about 52,900 deaths this year. The average five-year survival for patients with stage III colon cancer is around 80 percent, although between 25 and 35 percent of patients experience a recurrence of cancer during that time. The researchers say that they plan to conduct more detailed investigations of the biological effects of diet and lifestyle on colon cancer outcomes, including those with metastatic colon cancer and those diagnosed at younger ages, under age 50. The majority of Americans — as many as 57 percent — may be eating a diet that promotes inflammation, researchers at the Ohio State University found last year. In 2018, a Harvard study found that people who ate foods that promoted inflammation had a higher rate of colorectal cancer compared with people who ate the least foods, with a 22 percent higher risk for men than women. Eating white bread and drinking alcohol are linked to an increased risk for developing colorectal cancer. Whole grains have anti-cancer properties and eating fiber helps to reduce colorectal cancer risk, researchers told Fox News Digital in 2023. The next year, a study found potential risk for white bread intake. Alternatively, consuming more dark leafy greens, vegetables, nuts, whole grains, and protein sources that are high in omega-3 fatty acids can help fight inflammation, according to UCLA Health. The Mediterranean diet may be the most beneficial, Johns Hopkins Medicine notes. 'I want to emphasize that people really need to focus on their pattern of eating — as opposed to eating a few particular foods — to reduce inflammation,' Dr. Edwin McDonald, a gastroenterologist at UChicago Medicine, wrote. ' There's no miracle food out there that's going to cure people with chronic inflammation. You need to have an anti-inflammatory lifestyle and diet.'
Medscape
16-05-2025
- Health
- Medscape
Simple and Radical Hysterectomies Show Similar Survival
Long-term survival analysis reveals comparable outcomes between simple hysterectomy and modified radical hysterectomy (MRH) or radical hysterectomy (RH) in women with low-risk cervical carcinoma. METHODOLOGY: RH with bilateral pelvic lymphadenectomy has historically been the recommended treatment for patients with cervical cancer not desiring fertility. This procedure, which involves removal of cervix, uterus, parametria, and upper vagina, has achieved overall survival rates up to 90%. Despite high survival rates, RH carries 10%-15% risk for postoperative complications including hemorrhage, bowel dysfunction, ureteral fistula, voiding dysfunction, sexual dysfunction, and reduced quality of life. The new analysis included women diagnosed between January 2010 and December 2017 with International Federation of Gynecology and Obstetrics 2009 stage IA2 or IB1 squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix (< 2 cm) and clinically negative lymph nodes. Participants comprised 2636 women (mean age, 45.4 ± 11.4 years) with median follow-up of 85 months, including 982 who underwent simple hysterectomy, 300 with MRH, 927 with traditional RH, and 427 with unspecified MRH or RH. Risk assessment involved two multivariable models — one adjusting for nine baseline factors and another extending to include four additional clinical factors including surgical margin, lymphovascular space invasion, pathologic lymph node metastasis, and adjuvant treatment. TAKEAWAY: Seven-year survival rates were comparable between groups: 93.9% (95% CI, 91.9%-95.4%) for simple hysterectomy vs 95.3% (95% CI, 94.0%-96.3%) ( P = .07) for MRH or RH. = .07) for MRH or RH. Propensity score–balanced analysis showed similar adjusted survival rates at 3 years (98.3% vs 97.6%), 5 years (95.9% vs 96.5%), 7 years (94.5% vs 95.1%), and 10 years (89.8% vs 91.7%) between simple hysterectomy and MRH or RH groups. Sensitivity analysis for patients diagnosed between 2010 and 2013 demonstrated similar 10-year restricted mean survival time following simple hysterectomy vs MRH or RH (mean difference, −1.33; 95% CI, −3.69 to 1.03; P = .27). IN PRACTICE: 'In this cohort study, long-term survival was similar following [simple hysterectomy] vs MRH or RH, supporting the use of [simple hysterectomy] in select patients with low-risk early-stage cervical carcinoma,' the authors of the study wrote. SOURCE: This study was led by Christopher M. Tarney, MD, and Kathleen M. Darcy, PhD, from the Gynecologic Cancer Center of Excellence, Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center in Bethesda, Maryland. It was published online on May 15 in JAMA Network Open . LIMITATIONS: Researchers could not perform central surgicopathologic review of cases or evaluate details regarding treatments or recurrence rates. This study design inherently involved possibilities for selection bias, confounding, and loss to follow-up. Additionally, investigators were unable to explain utilization rates of simple hysterectomy between 2010 and 2017, examine data on late complications (especially bladder complications), time to disease failure and sites of failure, or investigate quality of life. DISCLOSURES: This study received funding through awards from the Uniformed Services University of the Health Sciences from the Defense Health Program to the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. Leslie M. Randall, MD, reported receiving grants from Merck, Genmab, Seagen, and the Gynecologic Oncology Group Foundation, along with personal fees from multiple pharmaceutical companies. John K. Chan, MD, disclosed receiving personal fees from various pharmaceutical companies, including AstraZeneca, Daiichi Sankyo, and GSK. Chad A. Hamilton, MD, reported receiving personal fees from GSK, AbbVie, Merck, and AstraZeneca. Kathleen N. Moore, MD, disclosed receiving personal fees from numerous pharmaceutical companies and serving in various organizational roles. Thomas P. Conrads, PhD, reported receiving personal fees from Thermo Fisher Scientific as a scientific advisory board member. Additional disclosures are noted in the original article.
National Post
14-05-2025
- Health
- National Post
Komodo Health's Real-World Evidence Platform Drives 31 Patient Journey Research Studies at ISPOR 2025
Article content Comprehensive Patient Journey Data Links Clinical Outcomes to Real-World Impact, Addressing Critical Evidence Gaps in Oncology, Neurology, Cardiovascular, Metabolic, and Rare Diseases Article content Article content MONTREAL — Komodo Health today announced that its healthcare intelligence platform enabled 31 research studies being presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) global conference. These include three studies led by Komodo researchers and 27 collaborative studies with academic institutions, Life Sciences companies, and healthcare organizations. Article content 'The volume and diversity of research powered by our healthcare insights underscore the growing demand for high-quality real-world data combined with advanced analytical capabilities,' said Arif Nathoo, MD, CEO and Co-Founder, Komodo Health. 'By connecting individual patient journeys to large-scale health outcomes, we're enabling researchers to uncover actionable insights that improve clinical practice, healthcare policy, and patient outcomes.' Article content The ISPOR 2025 research presentations demonstrate the value of Komodo's real-world evidence across a wide range of therapeutic areas, including: Article content Oncology: Salix Pharmaceuticals, Analysis Group, and Bausch Health studied the economic burden of opioid-induced constipation among patients with or without cancer; Cardiovascular disease: Veradigm examined the discordance between apolipoprotein B and low-density lipoprotein cholesterol levels in predicting incident hypertension risk and how it correlates to differential hypertension development patterns between diabetic and non-diabetic populations; Metabolic disorders: Novo Nordisk studied non-invasive diagnostic approaches and earlier interventions for metabolic dysfunction-associated steatohepatitis (MASH); Neurology: Jazz Pharmaceuticals analyzed healthcare resource utilization and costs among individuals with narcolepsy or idiopathic hypersomnia (IH) who are considered at higher risk for negative clinical outcomes associated with sodium (due to underlying cardiovascular, cardiometabolic, or renal conditions); and Rare disease: Chiesi analyzed medical claims data to better understand healthcare resource utilization patterns among Fabry disease patients Article content Three poster presentations by Komodo researchers also showcase methodological advances: Article content Komodo provides a multidimensional view of 330+ million patient journeys by linking de-identified claims data with specialty datasets, including lab results, genomics, and demographic information — through its platform to address fundamental challenges in health economics and outcomes research (HEOR). Whereas HEOR teams have traditionally relied on fragmented, incomplete datasets that provide only narrow snapshots of patients' in-network healthcare experiences, Komodo's platform enables researchers to link disparate datasets without the months typically spent on data cleaning and integration. The option to enhance disease understanding at the patient level with lab, EHR, patient insurance, race and ethnicity, and mortality data enables teams to self-serve cohort feasibility and insights. This ability accelerates study planning timelines by weeks and generates more accurate estimates of treatment patterns, healthcare resource utilization, and costs. Article content 'By closing critical data gaps and providing a patient-centric approach to HEOR, our powerful, all-in-one platform brings clean, connected, and compliant real-world data together,' Nathoo added. 'We eliminate the need for messy integrations, manual data wrangling, and coding cohorts from scratch, which enables HEOR teams to generate evidence faster. The inclusion of race, ethnicity, mortality, and other demographic insights at a near-census level also allows researchers to better model the clinical and financial impacts of new therapies across diverse populations, addressing the reality that disease burden is not borne equally across demographic groups.' Article content Article content Article content Article content Article content Contacts Article content Media Contacts: Rowena Kelley 858.255.1651 media@ Article content Article content Article content
